c-Jun knockdown sensitizes osteosarcoma to doxorubicin
Dass, Crispin R and Khachigian, Levon M and Choong, Peter F. M (2008) c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Molecular Cancer Therapeutics, 7 (7). pp. 1909-1912. ISSN 1535-7163Full text for this resource is not available from the Research Repository.
The oncogene c-Jun has been found to be up-regulated in a variety of cancers, including osteosarcoma. Doxorubicin is a frontline chemotherapeutic against osteosarcoma, but is limited by toxicity. DNAzymes are oligonucleotides capable of specific catalysis of target mRNA. A biocompatible c-Jun DNAzyme nanoparticle formulated from chitosan regressed the growth and metastasis of preestablished tumors, especially in combination with doxorubicin. In vitro data confirmed that c-Jun knockdown chemosensitized these cells to doxorubicin treatment. c-Jun down-regulation–mediated tumor inhibition also led to concomitant decreased osteolysis. Clinically, knockdown of c-Jun with chitosan nanobiotechnology may proffer an improved treatment outcome for osteosarcoma.
|Uncontrolled Keywords:||ResPubID18862. c-Jun, osteosarcoma, doxorubicin, DNAzymes, tumors, mRNA, chitosan, bone, cancer|
|Subjects:||RFCD Classification > 320000 Medical and Health Sciences
Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
FOR Classification > 1117 Public Health and Health Services
|Date Deposited:||16 Sep 2011 04:04|
|Last Modified:||10 Mar 2015 06:16|
|ePrint Statistics:||View download statistics for this item|
|Citations in Scopus:||18 - View on Scopus|
Repository staff only